U.S. Stock News

Circle Internet Group, Inc. recently received a limited purpose trust charter from the New York Department of Financial Services for Circle Internet Trust Company LLC, doing business as Circle New York Trust, formalizing its regulatory status in one of the world’s most stringent financial jurisdictions. This charter builds on Circle’s long relationship with New York regulators since its 2015 BitLicense, reinforcing USDC’s position within a highly regulated framework as blockchain-based...

Marriott International stock just took a sharp beat, sliding about 7% today from a previous close near US$372 to roughly US$347, even after posting headline results that looked strong on the surface. Adjusted diluted earnings per share for the quarter landed at US$3.19 and adjusted EBITDA reached US$1.59b, both solid prints for a global hotel operator tied closely to travel demand. The short term story is about that drop on your screen. The longer term story is about whether investors still...

Masimo (MASI) stock is in focus after the company received FDA 510(k) clearance for its pediatric Patient State Index sedation score, extending the SedLine brain monitoring suite to children four years and older. See our latest analysis for Masimo. The FDA clearance comes as Masimo’s share price sits at US$179.95, with a year to date share price return of 41.25% and a 1 year total shareholder return of 7.09%. This suggests momentum has picked up recently after weaker multi year total...

Main Street Capital has almost doubled investors' money over the past five years, yet its current share price around US$55.75 sits between two conflicting signals, with the Excess Returns intrinsic value estimate pointing to upside while earnings based multiples lean the other way. Main Street Capital has delivered a 93.5% total return over five years, which keeps expectations for future returns in sharper focus. Ongoing income generation from its investment portfolio can support views of...

Twist Bioscience stock came into this earnings print already heated after a strong run over the past quarter. The market pushed the share price up another 10.4% to about US$101 by the close after Q3 numbers hit. That kind of one day move suggests emotion may be in the driver’s seat. The key focus today is revenue momentum. Twist Bioscience reported Q3 revenue of US$118.4m and raised full year sales guidance to a range of US$456m to US$457m. At the same time the company is still reporting...

Supernus Pharmaceuticals stock climbed about 3% to roughly US$46, even as the company reported another quarterly loss. The headline this quarter is not the revenue line, which reached about US$219 million. The real story is the sharp hit to profitability, with basic earnings per share swinging to a loss of about US$1.01 and net income showing a loss of roughly US$58 million. For investors, today’s modest bounce comes against a backdrop of pressure on margins and a trailing twelve month loss...

CNH Industrial walked into this earnings day with a flat near term record and a rich valuation story. The stock had slipped over the past week and three months, yet it now trades at about $10.80, up roughly 5% on the session, and on a P/E of about 43x that sits well above peers. The headline is simple. Q2 showed modest revenue of about $4.8b and net income of $138m while margins over the past year remained thin and leverage coverage stayed uncomfortable. The market cheered the print anyway...

National HealthCare (NHC) stock has drawn fresh attention after recent trading, with the shares last closing at US$222.76. Investors are weighing this price against the company’s current fundamentals and recent return profile. See our latest analysis for National HealthCare. Although National HealthCare’s share price slipped around 1.5% over the last day and 3.6% over the past week, the stock still shows firm momentum, with a 31.5% 90 day share price return and a 134.9% 1 year total...

Aurinia Pharmaceuticals has delivered a 50.1% gain over the past three years, yet its valuation checks still point to the stock looking cheap on several fronts. Recent share price softness adds to the question of whether the current US$14.57 level is giving investors a discount or simply reflecting caution about the business. The 50.1% return over three years suggests patient shareholders have already seen meaningful value created, which raises the bar for new buyers. Future growth in...

In late July 2026, Carrier Global Corporation reported second-quarter 2026 results showing higher revenue of US$6,351 million but lower net income of US$501 million year over year and confirmed it had completed a US$7.52 billion share repurchase program launched in 2021, having bought back 126,876,374 shares in total. On the same day, Carrier Global raised its full-year 2026 sales guidance to approximately US$23 billion from about US$22 billion, signaling management’s confidence in the...

Douglas Dynamics went into this print with a stock that had already cooled, down over 16% across the past month, and the market clipped another 4.8% off the share price after the release. That reaction jars with the headline story. The company posted record Q2 revenue of US$214.6m and record adjusted earnings per share of US$1.22, both backed by stronger preseason demand for work truck attachments. For a business often seen as a weather call option, this quarter focused on profit quality...

Tradeweb Markets (TW) is back in focus after reporting second quarter 2026 results that showed higher revenue and net income compared with a year earlier, alongside ongoing dividends and recently completed share repurchases. See our latest analysis for Tradeweb Markets. Despite the solid second quarter update, Tradeweb Markets has seen its share price drift, with a 90 day share price return decline of 7.7% and a 1 year total shareholder return decline of 27.8%. However, the 3 year total...

Sportradar Group entered this earnings season with a stock that had already been under pressure over the past month. The latest report then triggered a sharp 15% slide to €12.34, as the market focused on a fresh quarterly net loss and softer sentiment around growth bets in sports data and betting technology. Beneath that reaction, the headline was different. Sportradar Group reported €378m of Q2 revenue and solid adjusted earnings before interest, tax, depreciation and amortisation, supported...

Global growth downgrades, sticky inflation and supply chain disruptions are pushing investors to reassess where risk and resilience really sit in their portfolios. At the same time, governments are increasing funding for renewable energy and green technologies, which can reshape expectations for future cash flows and policy support across the sector. This article looks at how that mix of pressure and support may affect selected renewable energy stocks today. It will walk through 3 stocks from...

Kosmos Energy came into this earnings print with a value label attached, trading on a low price to sales multiple and sitting at US$2.69 at the prior close. The stock then slipped nearly 6% to US$2.53 as the market digested the Q2 2026 release. That move was accompanied by a shift back into profit, with basic earnings per share of US$0.31 and net income of US$184.8m on US$607.6m of revenue. For a company known for persistent losses and balance sheet worries, this quarter places profitability...

First Horizon stock has more than doubled over the past three years, yet the latest intrinsic value work using the Excess Returns model suggests the market price may still be below what the underlying business justifies. First Horizon has returned 108.5% over the past three years, which puts extra focus on whether recent gains already reflect its fundamentals. The company run stress test results, which show capital ratios staying well above regulatory minimums in severe scenarios, can...

Graham Holdings Company reported past second-quarter and first-half 2026 results, with revenue rising to US$1,302.51 million and US$2,538.50 million, and net income increasing to US$281.10 million and US$310.21 million, respectively, alongside much higher earnings per share from continuing operations versus a year earlier. The jump in earnings per share from continuing operations, from US$8.35 diluted a year ago to US$64.86, highlights a very large improvement in profitability across the...

Indivior Pharmaceuticals stock just shed 6.6% in a single session, yet the latest quarter reads more like a profitability step change than a collapse in confidence. The company printed Q2 basic earnings per share of US$1.02 on revenue of US$343 million, both comfortably above the prior quarter levels. Over the trailing twelve months that has translated into a 26.7% net margin against just 9.2% a year earlier. The market is focusing on the headline price drop. The earnings story is about a...

Rising inflation, hawkish comments from Federal Reserve officials and uncertainty around the next move on interest rates are reshaping how investors think about banks and insurers. Some stocks could benefit if higher rates support lending margins or investment income, while others may face pressure from funding costs and credit risks. This article focuses on three stocks from our Financial Sector screener that appear closely tied to these rate and policy trends. You will see how each stock is...

FedEx stock has returned 76.0% over the past year, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and earnings multiples currently lean toward the shares trading below what the fundamentals imply. That sets up an important check for investors on whether the recent gains have simply closed a gap or if the market is still pricing FedEx cautiously. FedEx has gained 76.0% over the past year, which puts the current share price in sharp focus against its underlying earnings power...

The market just marked TG Therapeutics down hard, with the stock dropping about 11% the day after earnings, even as the core multiple sclerosis drug story looked stronger on the surface. Investors came in after a solid 12 month run, only to be met with an earnings print that paired powerful BRIUMVI revenue of about US$228 million with a sharp hit to bottom line profit. The headline this quarter is margin pressure. Heavy manufacturing related charges cut reported net income to US$7.8 million...

Ocular Therapeutix stock inched up about 3% to US$8.40 after earnings, a modest move for a biotech that has been drifting lower over the past quarter. The headline is not about a sudden swing into profit. It is about how much revenue growth investors are willing to pay for when the losses remain heavy. Quarterly revenue sat in the low teens in millions of US dollars, while net loss stayed deep in the tens of millions. That mix keeps the spotlight on the long term. For anyone looking at Ocular...

Lantheus Holdings stock has delivered very strong returns over the past few years, yet the current price sits close to the agreed cash offer from Curium, which raises questions about how much upside is left in the valuation. Over the past 5 years, Lantheus Holdings has returned about 294.0%, which puts recent share price moves into the context of a very strong multi year run. The agreed Curium acquisition, with a headline value of up to US$8b tied to milestones, can anchor expectations for...

Compugen stock barely flinched after earnings, ticking up about 1% to US$2.38, yet the real story sits far beyond today’s modest move. You are looking at a biotech that has just posted another small quarter of revenue at US$2.6m and a quarterly net loss of about US$7m, while still carrying a price tag of only 6.4x trailing earnings. The time horizon is the tension. In the short term, Q2 is about controlled burn and a long cash runway into 2029. Over multiple years, the debate shifts to...